Belite Bio to Participate in the 2025 Maxim Growth Summit

SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the Maxim Growth Summit on October 22, 2025.

To schedule a one-on-one meeting with management, please reach out to your Maxim representative.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
[email protected]

Julie Fallon
[email protected]

You May Also Be Interested In

• ZenaTech Unveils Stacklens™, AI-Powered Smart Safety Glasses Built for Field Technicians and Industrial Workers
• Driven Tech Joins Open Secure AI Alliance and Contributes AI Security RFC
• AINewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Secures Initial 10 MW Hosting Agreement with Potential $450 Million Contract Value